Biodesix
Biodesix Raises Approximately $16.3M in Sale of Common Shares, Amends $30M Term Loan
The term loan amendment includes modifications to restrictive financial covenants to provide the firm with additional financial flexibility.
Biodesix, Spesana Partner to Improve Workflows for Lung Cancer Molecular Diagnostic Tests
Startup Spesana's digital platform will integrate EMR, lab information, and MDx data to automate clinical workflows, tumor boards, and clinical trial management.
Biodesix Q3 Revenues Down 29 Percent on Lower COVID-19 Test Sales but Tops Estimates
The company said that the decline in SARS-CoV-2 test revenues was expected amid growing vaccination rates and the adoption of non-laboratory testing for the virus.
Understanding how an AI-driven algorithm makes its decisions may help inspire greater physician confidence in the technology.
Biodesix Q2 Revenues Shoot up but Fall Short of Wall Street Expectations
COVID-19 testing revenues grew to $6.0 million while lung diagnostic revenues rose to $4.8 million and biopharma revenues increased to $1.0 million.
May 11, 2021
Biodesix Q1 Revenues Soar on COVID-19 Testing
Mar 24, 2021
Biodesix Secures $30M Term Loan
Dec 11, 2020
Biodesix Q3 Revenues Rise Sharply
Nov 23, 2020
Three Investment Banks Initiate Coverage of Biodesix
Oct 28, 2020
Biodesix Prices $72M IPO
Aug 17, 2020
Mar 20, 2020
Biodesix, Bio-Rad Partner on Coronavirus Test
Jul 10, 2018
Jul 9, 2018
Biodesix Acquires Integrated Diagnostics
Mar 5, 2018